NGS-Based RNA-Sequencing Industry is Growing at a CAGR of 20%

NGS-based RNA-sequencing Market growth is driven mainly by the advantages of RNA-seq over conventional technologies; an increasing number of RNA-seq grants; rising number of research activities involving RNA-seq; and rapid growth in precision medicine market.

NGS-based RNA-sequencing Market: Impact Analysis

1. NGS-Based RNA-Sequencing: Market Overview
2. Geographical Snapshot of the NGS-Based RNA-Sequencing Market
3. Rapid Growth in Precision Medicine
4. Growing Number of Research Activities Involving RNA-Seq
5. Increasing Applications of RNA-Seq in Research ( Cancer and Agricultural)

The NGS-based RNA-sequencing market size is estimated to grow from USD 1.7 billion in 2019 to USD 4.2 billion by 2024, at a CAGR of 20.0%.

Key Questions Addressed in The Report:

1. Who are the top 10 players operating in the global NGS-based RNA-sequencing market?
2. What are the drivers, restraints, opportunities, and challenges in the NGS-based RNA-sequencing Industry?
3. What are the opportunities for stakeholders and provide details of the competitive landscape for key players?
4. What will be growth of NGS-based RNA-sequencing in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa?
5. What revenue impact will platforms and consumables have in the market during the forecast period?

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102977816

RNA Sequencing Platforms and Consumables:

The RNA sequencing platforms & consumables segment accounted for the largest share of the NGS based RNA sequencing market. This can be attributed to continuous technological advancements witnessed in the market and the increasing availability of innovative & cost-effective sequencing platforms.

Sequencing by Synthesis:

The sequencing by synthesis segment accounted for the largest share of this market in 2018. The dominant market position of this segment is attributed mainly to the development of new and advanced NGS platforms and the increasing demand for Illumina’s systems, as it is the major provider of NGS platforms that use the SBS technology (including the HiSeq and MiSeq series, NextSeq, and HiSeq X Ten).

North America an Europe to Dominate the Industry:

Based on the region, the market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest share of the NGS-based RNA-sequencing market. This can primarily be attributed to the government support through funds for genomics research, advancements in RNA-Seq products, growing prevalence of target diseases, growing research on cancer and inherited rare diseases, and the strong presence of key players such as Illumina (US), Thermo Fisher (US), and Agilent Technologies (US).

Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=102977816

Key Players:

Illumina (US), Thermo Fischer Scientific (US) and Oxford Nanopore (UK), Agilent Technologies, Inc. (US), BGI (China), PerkinElmer Inc. (US), QIAGEN (Germany), Eurofins Scientific (Luxembourg), F. Hoffmann-La Roche Ltd (Switzerland), Takara Bio Inc. (Japan), GENEWIZ, Inc. (US), Hamilton Company (US), Macrogen (South Korea), Zymo Research (US), and Tecan Genomics, Inc. (Switzerland) among others are the major players operating in the NGS-based RNA-sequencing market.